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Purpose. Primary tinnitus has a severe negative influence on the quality of life of a significant portion of the general population.
Acoustic coordinated reset neuromodulation is designed to induce a long-lasting reduction of tinnitus symptoms. To test acoustic
coordinated reset neuromodulation as a treatment for chronic, tonal tinnitus under real life conditions, an outpatient study “RESET
Real Life” was commissioned by ANM GmbH. Herein we present the results of this study. Methods. In a prospective, open-label,
nonrandomized, noncontrolled multicenter clinical study with 200 chronic tinnitus patients, tinnitus questionnaire TBF-12 and
Global Clinical Improvement-Impression Scale (CGI-I7) are used to study the safety and efficacy of acoustic coordinated reset
neuromodulation. 189 patients completed the last 12-month visit, 11 patients dropped out (8 because of nontreatment related reasons;
2 because tinnitus did not change; and 1 because tinnitus got louder). Results. Acoustic coordinated reset neuromodulation caused
a statistically and clinically significant decrease in TBF-12 scores as well as in CGI-I7 after 12 months of therapy under real life
conditions. There were no persistent adverse events reported that were related to the therapy. Conclusion. The field study “RESET
Real Life” provides evidence for safety and efficacy of acoustic coordinated reset neuromodulation in a prospective, open-label, real
life setting.
1. Introduction
The perception of sound in the absence of a corresponding
sound source is the definition of primary tinnitus, which, in
its chronic form, affects 10–15% of the general population in
industrialized countries [1]. About 2% are severely impaired
in their quality of life because of chronic tinnitus and rely on
professional help [2, 3].
A growing body of evidence suggests that altered spectral
power of neural signals, that is altered statistical distribution
of power over frequency, as measured by EEG/MEG, is the
neuronal fingerprint of primary tinnitus [4–10] and that the
perception of tinnitus requires the involvement of a larger
network of brain areas [11–14]. There are now several reports
of oscillatory brain activity changes, recorded via EEG, in
tinnitus patients that reveal a decrease in alpha wave power
(10–14Hz) within the primary auditory cortices [4, 9] and
an increase in slow wave delta activity (1.5–4Hz) [4, 9, 15]
when compared to controls. Slow wave oscillations have
been attributed to hyperpolarization of thalamic nuclei as
Hindawi Publishing Corporation
BioMed Research International
Volume 2015, Article ID 569052, 8 pages
http://dx.doi.org/10.1155/2015/569052
2 BioMed Research International
a result of auditory deafferentation, which may enhance
thalamocortical oscillations thus inducing pathological neu-
ral synchrony that has been proposed as the progenitor of
tinnitus perception [16].
Various approaches have been investigated for the treat-
ment of primary tinnitus [17] such as cognitive behavioral
therapy [18], hearing aids [19], sound maskers [20], tinni-
tus retraining therapy [21], medication [22–24], hyperbaric
oxygen therapy [25], acupuncture [26], andneuromodulation
[27]. However, meta-analytic evidence has only been found
for a beneficial effect from cognitive behavioral therapy on
quality of life of tinnitus patients but not on tinnitus loudness
[18].
Acoustic CR neuromodulation is a noninvasive acous-
tic stimulation therapy for primary tonal tinnitus, which
was developed computationally [28–30]. The therapy is
designed to counteract pathological neural synchrony by
sustainably reducing the strength of synaptic connectivity
between neurons within an affected cell population [8, 14].
In order to target the synchronized focus in the tonotopically
organized auditory cortex, four acoustic tones are delivered
with different frequencies centered around the characteristic
frequency of the patient’s tinnitus percept [8]. This approach
aims to reduce pathologically enhanced neural synchrony
within the primary auditory cortices which, in turn, results
in a net decrease in effective connectivity across the global
brain network involved in tinnitus perception [9, 14] along
with a decrease of tinnitus-related abnormal cross-frequency
coupling [31]. The tonotopically targeted stimulation tones
are presented to the patient via a handheld tone generator
(T30 CR neurostimulator), which utilizes earphones that
are adapted from receiver-in-the-ear-canal (RIC) hearing
aids. These RIC adapted earphones ensure that the patient’s
external auditory meatus is not occluded by the headphone
receiver and enables a high degree of acoustic environmental
transparency during stimulation tone presentation.
First evidence for acoustic CR neuromodulation as being
an effective therapy for primary tonal tinnitus was provided
by a randomized proof of concept trial: a statistically and clin-
ically significant improvement in tinnitus questionnaire (TQ)
and visual analogue scale (VAS) for loudness/annoyance
scores was obtained [8, 32, 33]. Furthermore, the analysis
of EEG recordings demonstrated a change in pathologically
altered EEG power (i.e., 𝛼, 𝛾, and 𝛿 band) towards normal-
ization [8, 9].
To consolidate the results from the RESET proof of
concept study in a larger patient population and in a real
life outpatient setting, a second study, named RESET Real
Life (RRL, ClinicalTrials.gov: NCT01435317) was conducted.
The goal of the interventional multicenter RRL study was
to collect data for the confirmation of efficacy and safety
of twelve months of acoustic CR neuromodulation as a
treatment of chronic tinnitus using the CE marked therapy
system T30 CR. Tinnitus burden was assessed with the TBF-
12 [34]; tinnitus loudness and annoyance were measured
with numeric rating scales (NRS, ranging from 0 to 100)
and clinical global improvement with the CGI-I7. In total,
200 patients were included in this prospective, open-label,
nonrandomized, noncontrolledmulticenter study at 23 study
sites. Herein, we present the final data after 12 months of
therapy.
2. Materials
200 patients were enrolled in this multicenter clinical study
on Acoustic CR neuromodulation between November 2011
and May 2012 in 23 study centers run by ENT specialists
located in Germany. Inclusion criteria were symptomatic
primary tonal chronic tinnitus (≥3 months), <60 dB hearing
loss for all tested frequencies (125Hz–8 kHz), and men and
women ≥ 18 years old. Patients were not included in the study
if they were found to be suffering from serious neurologic,
psychiatric, or otological disease, objective tinnitus (e.g., tin-
nitus caused bymuscle movements, vascular noise, and other
somatosounds), Meniere’s disease, and tinnitus triggered by
craniomandibular disorders.
Regular visits took place 0.5, 1, 2, 3, 6, 9, and 12 months
after treatment start. The mean age of the patients was 50.6
years at study start, and 76.3% of the patients were male
(Table 1). 62.1% of patients had undergone two or more
tinnitus treatments prior to acoustic CR neuromodulation
without significant relief. Among them 18.7% of patients had
undergone more than 5 previous tinnitus treatments. Only
15.2% of patients were treated with Acoustic CR neurostim-
ulation as a first line therapy. Most of the patients (68.2%)
suffered from bilateral tinnitus (see Table 1).
Subjects were asked what they believe was responsible
for inducing their tinnitus. We are aware about the lim-
ited reliability of subjective causal attributions to tinnitus
onset. Nevertheless, the answer to this question provides
some orientation about individual etiologic factors [35, 36].
19 (9.5%) patients responded that it is noise trauma, 22
(10.9%) hearing problems, 95 (47.3%) stress, and 65 (32.8%)
other reasons (multiple responses were allowed). The tin-
nitus severity (based on the initial TBF-12 measurement)
was slight (no handicap) for 31.8% (TBF-12 0–8 pts), mild
for 34.4% (TBF-12 9–12 pts), moderate for 24.1% (TBF-
12 13–17 pts), and severe for 9.7% of the patients (TBF-
12 18–24 pts). Tinnitus duration was less than six month
for 2.0%, between six months and four years for 32.0%,
between four years and ten years for 29.4%, and more than
ten years for 36.6% of the patients. 43.1%/11.3% showed
no hearing impairment (averaged/maximal hearing impair-
ment ≤20 dBHL), 52.8%/19.5% a mild hearing impairment
(averaged/maximal hearing impairment between 20 dBHL
and 40 dBHL), 4.1%/42.0% a moderate hearing impairment
(averaged/maximal hearing impairment between 40 dBHL
and 60 dBHL), and 0.0%/27.2% a severe hearing impairment
(averaged/maximal hearing impairment >60 dBHL).
The treatment with acoustic CR neuromodulation
required regular visits to ENT clinics. At the first visit,
a thorough pitch matching process was carried out to
determine the tinnitus frequency. Based on the evaluated
tinnitus frequency 𝑓
𝑇
, four stimulation tones were defined,
two below and two above the individual tinnitus frequency
(frequency range: [0.76𝑓
𝑇
: 1.4𝑓
𝑇
]). The amplitudes of the
stimulation tones were adjusted in order to ensure that
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Table 1: Demographic data of study population.
Gender
male 151 (76.3%)
female 47 (23.7%)
Age
mean (std.) 50.6 yrs (10.4)
Perception of tinnitus
unilateral 63 (31.8%)
bilateral 135 (68.2%)
Pretreatment
none 30 (15.2%)
one 45 (22.7%)
≥two 123 (62.1%)
Cause of tinnitus
noise trauma 19 (9.5%)
hearing problems 22 (10.9%)
stress 95 (47.3%)
Tinnitus severity
slight (no handicap) 62 (31.8%)
mild 67 (34.4%)
moderate 47 (24.1%)
severe 19 (9.7%)
Tinnitus duration
<6 months 4 (2.0%)
6 months to 4 years 63 (32.0%)
4 years to 10 years 58 (29.4%)
>10 years 72 (36.6%)
Hearing impairment
250Hz–8.000Hz
(averaged/maximal)
≤20 dBHL 84 (43.1%)/22 (11.3%)
20 dBHL–40 dBHL 103 (52.8%)/38 (19.5%)
40 dBHL–60 dBHL 8 (4.1%)/82 (42.0%)
>60 dBHL 0 (0.0%)/53 (27.2%)
The information concerning the cause of tinnitus is based on a self-
assessment of the patient and the tinnitus severity is based on the TBF-
12 scores (missing values are not taken into account, the total number of
subjects varies between variables, and percentages are calculated without
taking missing values into account). Hearing impairment is listed with two
values: the averaged hearing impairment (in dBHL asmeasured by pure tone
audiometry as described inDINEN ISO8253-1within the range from250Hz
to 8.000Hz), for example, averaged over all frequencies of the audiogram,
and themaximal hearing impairment, for example, themaximal impairment
observed at one frequency.
all tones were comfortably audible, at the same subjective
loudness level, and slightly above the patient’s hearing
threshold.
With this information (frequency and amplitude of stim-
ulation tones), the handheld T30 CR device was programmed
with a randomized tone sequence which consisted of the
repetitive application of the four stimulation tones with a
repetition rate of 1.5Hz. Short pauses within the stimulation
signal (CycOn = 3, CycOff = 2) are utilized in order to
enhance the process of unlearning pathological tinnitus
activity [37]. The stimulation pattern containing the four
stimulation frequencies is designed to induce a phase reset of
abnormal delta oscillations at different locations within the
tonotopically organized auditory cortex (see Figure 1).
The therapy was applied using the T30 CR neurostim-
ulator, which consists of a programmable, battery-powered
device combined with a customized, open fit earphone that
utilizes a receiver-in-the-ear-canal (RIC) technology. The
prescribing clinician uses propriety software to program the
T30 CR neurostimulator.The patients were asked to use their
T30 CR neurostimulator device every day for 4–6 hours,
applying the therapy signals either continuously or splitting
up the stimulation time into sessions not shorter than one
hour. Visits to the ENT clinic took place at the beginning
of the therapy and then 0.5, 1, 2, 3, 6, 9, and 12 months after
beginning of the therapy. At each visit to the ENT clinic, the
tinnitus tone was measured by a thorough pitch matching
process and the device was reprogrammed when the tinnitus
tone was found to have changed.
The primary outcome measure of the study is the
analysis of changes in tinnitus severity, measured by the
German version of tinnitus handicap inventory (TBF-12,
Tinnitus-Beeintra¨chtigungs-Fragebogen) or improvement of
the Clinical Global Impression-Improvement Scale (CGI-I7).
Improvement was defined as a statistically significant (𝑃 <
0.05) reduction of scores comparing baseline values to end of
treatment (visit after 12 months). All scores were obtained in
the off-stimulation situation.
The TBF-12 tinnitus handicap inventory consists of 12
questions leading to a total score of 24 points (worst result).
Scores were categorized depending on the score recorded:
slight (no handicap) (0–8 pts), mild handicap (9–12 pts),
moderate handicap (13–17 pts), and severe handicap (18–
24 pts) [38]. CGI-I7 consists of the seven categories: very
much improved,much improved, slightly improved, no change,
slightly worse, much worse, and very much worse, expressed
by the numbers 1 to 7 (1 equals the very much improvement
category).
For the final analysis, outcome measurements for the
full 12 months of therapy were analyzed. For the statistical
analyses the 𝑡-test was utilized to evaluate the TBF-12 and
the sign test to evaluate the CGI-I7.This final analysis reports
the results of the primary (TBF-12, CGI-17) and secondary
endpoints (numeric rating scale (NRS) for tinnitus loudness
and annoyance). Additionally, the patients were asked to
report their device usage pattern to allow for the assessment
of compliance.
The 𝑡-tests were applied as paired, one sided, equal
variances, equal sample size tests to TBF-12 (total score), NRS
loudness, and NRS annoyance. Scores before and after treat-
ment were compared. Null hypothesis was the acquisition
of equal mean scores before and after treatment. Alternative
hypothesis was the acquisition of smaller means after treat-
ment.The sign test was applied to CGI. CGI was grouped in 2
categories “improvement” and “equal/worse.”Null hypothesis
was the acquisition of same number of patients in “improve-
ment” and “equal/worse” category.Alternative hypothesiswas
more patients in the “improvement” category. Significance
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Figure 1: Stimulation signal of acoustic CR neuromodulation.
level was set to 0.05. No multiple testing corrections were
applied. Missing values in the data were treated as missing
for the analysis. Data from drop-out patients was treated by
LOCF (last observation carried forward). To determine the
predictors for therapy success receiver operating characteris-
tics (ROC), curves were calculated using the 12-month data.
TBF-12 total score, NRS loudness, and NRS annoyance were
used as potential predictors and therapy success was defined
as CGI-I7 ≤ 3.
The study was performed in accordance with good
clinical practice guidelines and local ethics committees. All
participating patients gave their written informed consent.
Independent external clinical research associates and a clini-
cal physician monitored the safety of the study. Data analysis
was performed by an external contract research organization.
3. Results
189 patients finished the 12-month treatment and 11 patients
dropped out for different reasons: eight stated nontreatment
related reasons; two stated that their tinnitus did not change;
and one stated that his tinnitus got louder.
The treatment was well tolerated and no serious adverse
events (AE) were reported. An adverse event was defined as
any untoward medical occurrence. Technical and handling
problems were also documented as AE for this study. 89
product-related AEs were reported. Of these 89 product-
related AEs, 40 were device related (i.e., technical and
handling problems, rapidly solved). The other 49 AEs are
considered to be therapy related. These were an additional
atonal noise (15), additional tinnitus tone (3), increase in
tinnitus burden (2), increase in loudness (13), tinnitus fre-
quency shift (1), headaches (2), anxiety (1), tinnitus frequency
increased to >10 kHz (2), discomfort (7), itching of ear canals
(2), and otalgia (1). All adverse events were recorded as being
temporary with no permanent or sustainable features.
After 12 months, TBF-12 (total score) showed a mean
reduction of 4.1 points (−37.9%) compared to baseline (𝑃 <
0.01, df = 191, 𝑡 = −12.3, Table 2, Figures 2(a) and 2(b)):
mean TBF-12 score at baseline was 10.8 points and after
3 (6/12) months 7.9 (7.5/6.7) points. After 12 months, the
number of patients within the TBF-12 categories moderate
and severe handicap decreased from 33.8% to 13.9%, while
Table 2: Results of TBF-12 and CGI-I7 scores.
(a)
Variable Visit [month] 𝑁 Mean SD Delta 𝑃 value
TBF-12 Score
0 195 10.8 5.0 n.a. n.a.
3 193 7.9 4.7 −27.3% <0.01
6 193 7.5 4.7 −30.8% <0.01
12 195 6.7 5.0 −37.9% <0.01
(b)
CGI-I7 Patients
(after 12 months,𝑁 = 196) Number Relative number 𝑃 value
Very much improved (1) 17 8.7%
<0.01
Much improved (2) 49 25%
Slightly improved (3) 65 33.2%
No change (4) 48 24.5%
Slightly worse (5) 14 7.1%
Much worse (6) 2 1%
Very much worse (7) 1 0.5%
the number of patients within the category slight (no hand-
icap) increased from 31.8% to 64.1%. The TBF-12 based effect
size of the treatment is 0.89, which corresponds to a large
effect size.
At the visit after 12 months the results of CGI-I7 revealed
that 131 (66.9%) patients reported an improvement of their
tinnitus, that is, CGI-I7 categories 1, 2, or 3 (𝑃 < 0.01, 𝑘 = 131,
𝑁 = 196, Table 2, Figure 2(c)), 24.5% felt no change (category
4), and 8.6% reported feeling that their tinnitus had become
worse (categories 5, 6, and 7) (Table 2). After 3 months of
treatment 58.59% (𝑃 < 0.01, 𝑘 = 116, 𝑁 = 198) of the
patients reported an improvement of their tinnitus.
After 12 months of treatment the loudness of tinnitus, as
obtained by a numeric rating scale (0–100), was reduced by
11.1 points (18.9%) compared to baseline (𝑃 < 0.01, df = 194,
𝑡 = −4.53, Table 3): mean NRS loudness at baseline was
58.6 points and after 3 (6/12) months 53.7 (51.0/47.5) points.
Tinnitus related annoyance (also obtained by a numeric
rating scale (0–100)) was reduced by 14.7 points (25.2%) after
12 months of treatment as compared to baseline (𝑃 < 0.01,
df = 197, 𝑡 = −3, 14, Table 3). When asked if they are
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Figure 2: (a) TBF-12 scores at baseline and after 3, 6 and 12 months of treatment. (b) Relative TBF-12 change for the individual patients.
The position of the bar on the 𝑥-axis indicates the TBF-12 score at baseline. (c) Distribution of the CGI-I7 scores after 3, 6 and 12 months of
treatment. Stars indicate statistically significant results (󳀅󳀅𝑃 < 0.01).
Table 3: NRS scales for loudness and annoyance.
Variable Visit [month] 𝑁 Mean SD Delta 𝑃 value
NRS loudness
0 197 58.6 21.9 n. a. n. a.
3 198 53.7 20.6 −8.4% <0.05
6 197 51.0 21.5 −13.0% <0.01
12 196 47.5 24.9 −18.9% <0.01
NRS annoyance
0 198 58.3 25.2 n. a. n. a.
3 198 50.9 21.8 −12.7% <0.01
6 196 47.7 23.1 −18.2% <0.01
12 196 43.6 25.7 −25.2% <0.01
free of tinnitus, after 12 months of treatment 54.4% of the
patients reported either that they are tinnitus-free (4.1%) or
that tinnitus has no negative influence on their life any more
(50.3%).
In the course of the treatment the tinnitus pitch changed.
In average a reduction of tinnitus pitch was observed (−11.2%
after 3 months (𝑃 < 0.05, df = 361, 𝑡 = −2.44) and −15.6%
after 12 months of treatment (𝑃 < 0.01, df = 359, 𝑡 =
−3.20)). 55.6% of the patients showed a reduction of tinnitus
frequency of more than 10%, 33.1% of the patient showed an
increase of tinnitus frequency of more than 10%, and for the
remaining 11.3% of patients the tinnitus frequency changed
less than 10%. 80.0%/58.7% of patients with a reduction of
tinnitus frequency >10% showed an improvement of TBF-
12/NRS loudness, while this correlation is not significant
(chi-squared test). These tinnitus pitch changes imply an
adjustment of the therapy tones, which was done during the
regular visits.
Based on the TBF-12 scores at baseline the patients were
divided into four separate subgroups relating to tinnitus
severity slight (no handicap), mild, moderate, and severe. At
the end of the study, these scores were recorded as being
reduced by 34.1%, 36.4%, 39.0%, and 41.5%, respectively,
compared to the scores recorded at the beginning of therapy.
The NRS loudness was reduced for these same subgroups by
20.7%, 17.2%, 17.6%, and 24.7% while the NRS annoyance was
reduced by 18.5%, 21.9%, 32.2%, and 32.7%, respectively.
On average, the stimulation device was used by patients
for five hours per day. Compliance was 87% at the beginning
and fell to 73% after 12 months. “Compliance” was self-
expressed by the patients and was defined as at least 4-
hour daily stimulation. If the stimulation was split, then each
stimulation block should be at least 1 hour long.We calculated
receiver operating characteristics (ROC) curves to identify
predictors for therapy success (therapy success was defined
as CGI ≤ 3). Based on the 12-month data, the area under the
curve (AUC) was as follows: TBF-12 total score: 0.73, NRS
loudness: 0.82, and NRS annoyance: 0.83.
4. Discussion
This prospective, open-label, nonrandomized, noncontrolled
multicenter clinical study with 200 chronic tinnitus patients
demonstrates safety and good applicability, that is, good
patient compliance and low drop-out rate, of acoustic CR
Neuromodulation. 189 patients finished the 12-month treat-
ment, which demonstrates a good patient adherence.
The applied treatment, acoustic CR neuromodulation,
consists of a particular temporal pattern of stimulation
tones intending the induction of local desynchronization of
pathologically enhanced neuronal synchronization, which is
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the neuronal correlate of the tinnitus symptoms. By inducing
desynchronization, which also affects limbic structures asso-
ciated with the emotional perception of tinnitus [8, 9, 14],
the stimulation signals start the process of unlearning the
pathological signal, with the aim of resulting in a long-term
reduction of the tinnitus symptoms.
Analysis of the results of this multicenter clinical study
demonstrates significant results in both primary endpoints.
Both the TBF-12 and CGI-I7 results are statistically and clin-
ically significant after 12 months of treatment [39].The initial
tinnitus severity had only moderate effects on the treatment
effect. Furthermore, this study serves to demonstrate the
safety of acoustic CR neuromodulation, since, of all device-
related adverse events, none was serious (i.e., life threatening
or caused a hospitalization of the patient or disablement, etc.).
The final results of the RRL study, including data from
200 patients, support the results of the original RESET
study: similar results were obtained within the larger patient
population under “real life” conditions. While in the RESET
study after 3 months of treatment (group 1, same treatment
as in RRL) a change of −28.8% was obtained for the tinnitus
questionnaire (TQ), the current study revealed a change of
−27.3% in TBF-12 scores after a similar duration (visit after
3 months) and −37.9% after 12 months. This indicates that a
continuation of the treatment beyond the initial 3months can
be very beneficial for the patient. Continuous improvement
over the whole duration of the study was also found for
tinnitus loudness and annoyance and may suggest that a
treatment duration beyond 12 months may further increase
treatment efficacy.
The authors are aware of the limitations of this study,
which has been designed as an open study without a control
group.Thus, it is not possible to reach a final conclusion with
regards to what extent the observed effects are unspecific and
to what extent they actually represent the specific effects of
CR neurostimulation. However, the ongoing improvement of
patients over 12 months and their relatively high resistance
to previous treatments make placebo effects highly unlikely.
A spontaneous recovery is unlikely as well, given the relative
long tinnitus duration of most patients. In 88.1% of the
patients, a positive treatment effect over the first 3 months
(i.e., CGI-I7 ≤ 3 at month 3) correlated with a positive
treatment outcome after 12 months of therapy (i.e., CGI-I7
≤ 3 at month 12). 58.6% of the patients recorded a positive
effect after 3 months of treatment and 66.5% after 12 months.
TBF-12 improvement was seen to augment in this CGI-
I7-based responder population from −31.9% (3 months) to
−50.8% (12 months), NRS annoyance changed by −21.6% (3
months) and−35.6% (12months), andNRS loudness changed
by −16.7% (3 months) and −31.7% (12 months), while the
CGI-I7-based nonresponders showed onlymoderate changes
(TBF-12: −21.3% and −20.6%, NRS annoyance: +0.1% and
−5.4%, and NRS loudness: +3.9% and −0.3% at 3 months and
at 12 months, resp.). NRS annoyance resulted in the highest
value in the ROC test, which indicates that it is a good metric
for therapy success.Therefore, CGI-I7 combinedwith TBF-12
and NRS annoyance seems to be a reliable and easy to handle
set of questionnaires and metrics, which can be used in ENT
outpatient settings as indicators of treatment effects.
Our data (−37.9% mean change in TBF-12) can be com-
pared with recent results on effects of standard tinnitus care
and cognitive behavior therapy (CBT) [40]. Standard care
(hearing aid or tinnitus masker, 𝑛 = 161, 8-month treatment)
resulted in a change of tinnitus handicap inventory (THI)
and tinnitus questionnaire (TQ) by −11.9% and −13.3%,
respectively, while specialized care (CBT, 𝑛 = 175, 8 months
treatment) resulted in a change of THI andTQby−26.5% and
−26.2%, respectively.
Thus, in summary, the RRL study reveals that acoustic CR
neuromodulation, when applied for 12 months and used 4–6
hours per day in patients suffering from primary and tonal or
tone-like tinnitus, is a safe and feasible technique and exerts
encouraging effects on tinnitus loudness and severity.
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